| Code | CSB-RA047238A0HU |
| Size | US$210 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
CDKN1A, commonly known as p21, serves as a critical regulator of cell cycle progression and functions as a universal inhibitor of cyclin-dependent kinases. This protein plays a central role in the p53-mediated DNA damage response pathway, halting cell division to allow for DNA repair or directing cells toward senescence. Beyond its tumor suppressor functions, CDKN1A participates in cellular differentiation, apoptosis, and stress responses, making it an essential target for cancer research, cell cycle studies, and investigations into aging mechanisms.
This recombinant monoclonal antibody, generated against a synthetic peptide derived from human CDKN1A, offers the reproducibility and consistency that demanding research requires. As a sequence-defined reagent produced through recombinant technology, it eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The rabbit IgG format, purified by affinity chromatography, ensures high specificity for your target while minimizing background interference.
Validation testing demonstrates reliable performance in immunohistochemistry applications, with successful staining confirmed in paraffin-embedded human cervical cancer tissue and human placenta tissue at 1:100 dilution using citrate buffer antigen retrieval. These results indicate the antibody performs well across both pathological and normal human tissue contexts, providing flexibility for researchers examining CDKN1A expression patterns in diverse sample types. The antibody is also validated for ELISA applications, with recommended IHC dilutions ranging from 1:50 to 1:200 to accommodate optimization across different experimental systems.
This antibody supports investigations into tumor suppression mechanisms, cell cycle checkpoint regulation, senescence pathways, and therapeutic response studies where CDKN1A expression serves as a key biomarker.
There are currently no reviews for this product.